Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person lorlatinib-resistant ALK mutants don't bind lorlatinib

Class:IdFailedReaction:9715355
_displayNamelorlatinib-resistant ALK mutants don't bind lorlatinib
_doReleaseTRUE
_timestamp2021-05-04 17:36:45
authored[InstanceEdit:9724129] Rothfels, Karen, 2021-03-22
compartment[Compartment:70101] cytosol
[Compartment:876] plasma membrane
created[InstanceEdit:9715358] Rothfels, Karen, 2021-02-17
disease[Disease:1500689] cancer
edited[InstanceEdit:9725664] Rothfels, Karen, 2021-03-30
entityFunctionalStatus[EntityFunctionalStatus:9714057] loss_of_function of lorlatinib-resistant ALK mutants [plasma membrane]
input[ChemicalDrug:9702126] lorlatinib [cytosol]
[DefinedSet:9714053] lorlatinib-resistant ALK mutants [plasma membrane] [Homo sapiens]
isChimericFALSE
literatureReference[LiteratureReference:9713962] Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer
[LiteratureReference:9714001] Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
[LiteratureReference:9713940] Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review
[LiteratureReference:9714018] TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
modified[InstanceEdit:9724130] Rothfels, Karen, 2021-03-22
[InstanceEdit:9729590] Rothfels, Karen, 2021-04-30
[InstanceEdit:9729893] Rothfels, Karen, 2021-05-04
[InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
namelorlatinib-resistant ALK mutants don't bind lorlatinib
normalReaction
releaseDate2021-06-09
reviewed[InstanceEdit:9729891] Inghirami, Giorgio, 2021-05-04
reviewStatus[ReviewStatus:9821382] five stars
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9715361] R-HSA-9715355.2
summation[Summation:9714029] The following ALK mutants are resistant to inhibition by lor...
(hasEvent)[Pathway:9717329] lorlatinib-resistant ALK mutants [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by lorlatinib-resistant ALK mutants don't bind lorlatinib (9715355)
Follow Reactome